Galapagos presents promising data for CD19 CAR-T candidate GLPG5101 in treating non-Hodgkin lymphoma at EHA Congress 2024.
Galapagos reveals positive data for its CD19 CAR-T candidate, GLPG5101, in treating non-Hodgkin lymphoma at the European Hematology Association Congress 2024. The data highlights GLPG5101's potential as a new treatment option for patients. (400 characters)
June 14, 2024
4 Articles